Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2268)

[gutdrauf9]

Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness with HHS-BARDA
Gaithersburg, MD – (February 27, 2014)–/GlobeNewswire/Novavax, Inc. (Nasdaq: NVAX) announced today the execution of a contract modification to extend the base period of performance of its current contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Novavax’ recombinant seasonal and pandemic influenza vaccines. The contract was originally awarded in February 2011, with funding of up to $97 million over an initial base period ending in February 2014. Novavax and BARDA have agreed to amend the agreement to allow Novavax to continue to access the remainder of the $97 million in base period funding through September 2014. These funds will support the upcoming Phase 2 trial for our H7N9 vaccine candidate with Matrix-M, and activities relating to our quadrivalent seasonal influenza vaccine. BARDA has the ability to dedicate up to $79 million in additional funds to support Novavax’ later-stage development of these vaccines, during an option period currently anticipated to add two years to the overall performance period.
“Development of our seasonal and pandemic influenza products during the last three years under our contract with BARDA has allowed us to refine and develop influenza vaccine products while delivering important clinical trial results from our seasonal quadrivalent, avian H5N1, and most recently, avian H7N9 studies. While our original development plans anticipated utilizing the full amount of the contracted base-period funding within the three-year period, certain scope changes and development efforts resulted in delayed development timelines. Extending the base period allows us to continue to access the remaining base period budget as we initiate a pandemic H7N9 Phase 2 study early this year and prepare for additional Phase 2 and Phase 3 influenza clinical trials, which we expect would occur during the contract’s option period,” said Stanley C. Erck, the company’s CEO and President.

[Growth2012]

http://www.fool.com/investing/general/2013/12/21/3-humongous…

....

[Growth2012]

Antwort auf Beitrag Nr.: 46.069.436 von Betterway am 18.12.13 07:40:12

Ditto...

[Betterway]

Antwort auf Beitrag Nr.: 46.065.256 von jostawili123 am 17.12.13 15:43:09

Muss erst Kohle locker machen, bzw. evtl. umschichten....

[jostawili123]

Antwort auf Beitrag Nr.: 46.064.832 von Betterway am 17.12.13 14:44:34

Wieso erst Freitag einsteigen?

Bin bei 22% plus und kann deshalb so gut pennen (ohne "Erguss").

Wenn die 10/12 US$ nächstes Jahr kämen (wedbush) wäre das der Knaller.

[Betterway]

Werde am Fr, einsteigen !!! Gruß B.

[E-Jack-cool_at]

heute + 19% bei enormem Volumen (68 Mio) und hier pennen alle.
http://www.benzinga.com/analyst-ratings/analyst-color/13/12/…
Bin jetzt wieder im plus, mal sehen was noch kommt.

[rechnerhand]

http://seekingalpha.com/article/1890861-sell-organovo-buy-no…

[Betterway]

hmmmh, spannend, bin am Überlegen, ob ich noch einsteige ?? Was meint ihr dazu ??? Gruß B.

[noa9090]

bin ja echt erstaunt das sich auch andere mit Novavax beschäftigen.

http://www.cnbc.com/id/101025702

schöner Bericht!

Der große Shown - Down soll ja am 24-09-2013 sein. Bin gespannt was die Jungs von Novavax zu verkünden haben.

Schöner Move heute...